Achieve Life Sciences (ACHV) Price & Analysis

Compare

1,656 Followers

ACHV Stock Chart & Stats

$3.18

-$0.11(-3.08%)

At close: Jan 08 4:00 PM EST

$3.18

-$0.11(-3.08%)

Day’s Range― - ―

52-Week Range$1.84 - $5.31

Previous CloseN/A

Volume131.37K

Average Volume (3M)983.17K

Market Cap

$157.40M

Enterprise Value$32.95M

Total Cash (Recent Filing)$55.40M

Total Debt (Recent Filing)$9.96M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Nov 06, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding51,104,970

10 Day Avg. Volume723,654

30 Day Avg. Volume983,171

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.21

Enterprise Value/Revenue144.52

Enterprise Value/Gross Profit-10.98K

Enterprise Value/Ebitda-0.67

Forecast

1Y Price Target

$13.25

Price Target Upside316.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyCytisinicline significantly improves quit rates compared to placebo in individuals with chronic obstructive pulmonary disease (COPD), a high-need subgroup with historically poor outcomes on currently available smoking cessation therapies.

Commercial PotentialACHV shares do not currently reflect the full commercial potential of cytisinicline, especially given the limitations of existing therapies and the growing public health impact of smoking and vaping.

Regulatory MilestoneFDA acceptance of cytisinicline's NDA reduces clinical and regulatory risk.

Bears Say

Market PerceptionACHV's current enterprise value does not reflect the strength of the data supporting the NDA or the size of the addressable market, where peak cytisinicline sales could reach multiples of the current valuation.

Market ValuationThe market cap of approximately $144 million does not reflect the large market opportunity for a new smoking cessation product.

Achieve Life Sciences News

Achieve Life Sciences announces publication of data on cytisinicline

Achieve Life Sciences (ACHV) announced the publication of new data in Thorax demonstrating that cytisinicline significantly improved smoking...

24d ago

ACHV

Achieve Life Sciences promotes Craig Donnelly to Chief Operations Officer

Achieve Life Sciences (ACHV) announced the promotion of Craig Donnelly to Chief Operations Officer. Donnelly has been with...

28d ago

ACHV

Achieve Life Sciences Announces Leadership Change

Achieve Life Sciences ( ($ACHV) ) has provided an update. On September 11, 2025, Achieve Life Sciences announced...

8d ago

ACHV

Achieve Life Sciences’ Cytisinicline: A Promising Smoking Cessation Therapy with Strong Market Potential

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Achieve Life Sciences today and set a price...

24d ago

ACHV

Achieve Life Sciences Announces Leadership Change

Achieve Life Sciences ( ($ACHV) ) just unveiled an announcement. On September 5, 2025, Achieve Life Sciences announced...

1M ago

ACHV

Achieve Life Sciences names Mark Rubinstein interim CMO

Achieve Life Sciences (ACHV) announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer. Rubinstein...

1M ago

ACHV

Promising Outlook for Achieve Life Sciences: Buy Rating Backed by Cytisinicline’s FDA Progress and Market Potential

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Achieve Life Sciences, retaining the price target...

1M ago

ACHV

Buy Rating for Achieve Life Sciences: Strong Market Potential for Cytisinicline with FDA Approval Anticipated

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Achieve Life Sciences and keeping the price target...

1M ago

ACHV

Achieve Life Sciences announces FDA acceptance of cytisinicline NDA

Achieve Life Sciences (ACHV) announced that the U.S. Food and Drug Administration, FDA, has accepted the cytisinicline New...

1M ago

ACHV

Achieve Life Sciences initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $12 price target The...

2M ago

ACHV

Achieve Life Sciences’ Earnings Call Highlights Progress and Challenges

Achieve Life Sciences (($ACHV)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

ACHV

Optimistic Buy Rating for Achieve Life Sciences Driven by Strategic Advances and Financial Strength

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Achieve Life Sciences. The associated price...

2M ago

ACHV

Achieve Life Sciences Advances Cytisinicline Development

Achieve Life Sciences ( ($ACHV) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ACHV

Achieve Life Sciences reports Q2 EPS (37c), consensus (35c)

“This quarter represents a significant step forward for Achieve. After years of focused dedication, we’ve reached the major...

2M ago

ACHV

ACHV FAQ

What was Achieve Life Sciences Inc’s price range in the past 12 months?

Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.31 in the past 12 months.

What is Achieve Life Sciences Inc’s market cap?

Achieve Life Sciences Inc’s market cap is $157.40M.

When is Achieve Life Sciences Inc’s upcoming earnings report date?

Achieve Life Sciences Inc’s upcoming earnings report date is Nov 06, 2025 which is in 21 days.

How were Achieve Life Sciences Inc’s earnings last quarter?

Achieve Life Sciences Inc released its earnings results on Aug 07, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.366 by -$0.004.

Is Achieve Life Sciences Inc overvalued?

According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Achieve Life Sciences Inc pay dividends?

Achieve Life Sciences Inc does not currently pay dividends.

What is Achieve Life Sciences Inc’s EPS estimate?

Achieve Life Sciences Inc’s EPS estimate is -0.24.

How many shares outstanding does Achieve Life Sciences Inc have?

Achieve Life Sciences Inc has 51,104,970 shares outstanding.

What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?

Achieve Life Sciences Inc reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.366. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Achieve Life Sciences Inc?

Currently, no hedge funds are holding shares in ACHV

Achieve Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-120.11%

Trailing 12-Months

Asset Growth

-9.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Achieve Life Sciences (ACHV) Earnings & Revenues

Historic Earnings Reports

ACHV Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant advancements in regulatory submissions, strategic partnerships, and capital acquisition, indicating strong progress toward commercialization. However, the extended timeline to launch and potential pricing challenges present notable hurdles.View all ACHV earnings summaries

ACHV Stock 12 Month Forecast

Average Price Target

$13.25

▲(316.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.92,4.233846153846153,5.547692307692307,6.861538461538461,8.175384615384615,9.489230769230769,10.803076923076922,12.116923076923076,13.43076923076923,14.744615384615383,16.058461538461536,17.37230769230769,18.686153846153843,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.92,3.7146153846153847,4.509230769230769,5.303846153846154,6.098461538461539,6.893076923076923,7.687692307692307,8.482307692307693,9.276923076923076,10.071538461538461,10.866153846153846,11.660769230769231,12.455384615384615,{"y":13.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.92,3.4646153846153847,4.009230769230769,4.553846153846154,5.098461538461539,5.643076923076923,6.187692307692307,6.7323076923076925,7.276923076923077,7.821538461538461,8.366153846153846,8.91076923076923,9.455384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >